ENOVHealthcare · Medical DevicesThe 13 Wall Street analysts covering Enovis Corp. hold a median 12-month price target of $36 — +93.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 14 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Enovis Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (97): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (15): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ENOV, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +93.9% from it.
Of the 20 most recent actions, 2 moved their price target up and 8 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Oct 2026 | Needham | Maintains | Buy | $52 → $34 |
| 2 Sept 2026 | Citizens | Maintains | Market Outperform | — |
| 2 Sept 2026 | Citizens | Maintains | Market Outperform | $55 → $47 |
| 2 Sept 2026 | Freedom Capital Markets | Maintains | Buy | — |
| 2 Sept 2026 | Freedom Capital Markets | Maintains | Buy | $41 → $36 |
| 2 Sept 2026 | Wells Fargo | Maintains | Overweight | $39 → $33 |
| 2 Sept 2026 | Wells Fargo | Maintains | Overweight | — |
| 1 Sept 2026 | BTIG | Maintains | Buy | $40 → $36 |
| 1 Sept 2026 | BTIG | Maintains | Buy | — |
| 17 Aug 2026 | Canaccord Genuity | Maintains | Buy | — |
| 17 Aug 2026 | Canaccord Genuity | Maintains | Buy | $50 → $45 |
| 7 Aug 2026 | Wells Fargo | Maintains | Overweight | — |
| 7 Aug 2026 | Wells Fargo | Maintains | Overweight | $40 → $39 |
| 6 Aug 2026 | BTIG | Maintains | Buy | — |
| 6 Aug 2026 | BTIG | Maintains | Buy | $39 → $40 |
| 28 July 2026 | UBS | Assumes | Buy | $50 → $51 |
| 9 July 2026 | BMO Capital | Initiates | Outperform | $29 |
| 9 July 2026 | BMO Capital | Initiates | Outperform | — |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | $36 → $32 |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ENOV appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Enovis Corp. returned −40.2% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 82% of US stocks
Cheaper than 83% of US stocks
Cheaper than 79% of US stocks
Cheaper than 50% of US stocks
Higher than 35% of US stocks
Higher than 40% of US stocks
Higher than 75% of US stocks
Higher than 53% of US stocks
Higher than 10% of US stocks
Higher than 20% of US stocks
Higher than 52% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Enovis Corp. has a market value of $1.1B and an enterprise value of $2.5B.
Revenue in the twelve months to 30 June 2026: $2.3B. The latest quarter grew 3.2% year on year.
Net income over the same four quarters: −$1.1B, a −47.9% net margin.
Diluted earnings per share, trailing twelve months: $−19.26.
Free cash flow in the twelve months to 30 June 2026: $63.7M.
Trailing P/E: −0.9×; forward P/E: 5.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Enovis Corp. employs 7,802 people — $294K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Enovis Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Enovis announced an investor conference call and live webcast for Thursday, November 5, 2026, at 8:30 a.m. Eastern Time, to discuss its third-quarter 2026 financial results. The company said it will issue an earnings press release earlier that morning.
Why it matters — ENOV watchers can note when the company will release its quarterly results and discuss them with investors.
The American Academy of Orthopaedic Surgeons announced that Enovis has expanded its support of the AAOS Registry Program, becoming the first industry partner to sponsor multiple AAOS registries — adding the Shoulder & Elbow Registry to its existing support of the American Joint Replacement Registry.
Why it matters — For Enovis (ENOV) watchers, the expanded multi-registry sponsorship signals a deeper partnership with a leading orthopaedic organization and broadened industry engagement in its segment.
A medical device company insider purchased 7,598 shares at a weighted average price of $19.74 per share, for a total investment of roughly $150,000. The transaction represented about 14% of the executive's prior equity stake in the company.
Why it matters — An executive increasing their stake can signal insider confidence in the company, which is notable for Enovis Corp. watchers monitoring insider activity.
Enovis (ENOV) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. The upgrade is expected to support the stock's performance in the near term.
Why it matters — The upgrade signals increased analyst confidence in Enovis's earnings outlook, which a stock watcher would weigh when assessing the company's recent momentum.
Enovis (ENOV) has become technically oversold after losing 33% over four weeks, which analysts suggest may indicate exhaustion of selling pressure. Wall Street analysts have also been revising earnings estimates higher, together pointing to a potential near-term trend reversal for the stock.
Why it matters — For Enovis watchers, the combination of oversold technical conditions and rising earnings estimate revisions could signal a possible turning point after the stock's sharp decline.
The 13 Wall Street analysts covering Enovis Corp. have a median 12-month price target of $36, with estimates ranging from $24 to $47. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Enovis Corp., 12 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Enovis Corp. 79 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Enovis Corp. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (97 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +93.9% from the last close, and Ticker Nerd's factor model ranks Enovis Corp. 79 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Enovis Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENOV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $24 to $47 over the next 12 months.
Enovis Corp. returned -40.2% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Enovis Corporation is a medical technology company focused on developing clinically differentiated solutions for musculoskeletal health. Enovis Corporation designs, manufactures, and distributes medical devices and services used across the patient care continuum, including injury prevention, rehabilitation, pain management, physical therapy, and reconstructive surgery.
The most recent item we track (GlobeNewsWire, 8 Oct 2026): "Enovis to Host Third Quarter 2026 Results Conference Call on November 5th". Enovis announced an investor conference call and live webcast for Thursday, November 5, 2026, at 8:30 a.m. Eastern Time, to discuss its third-quarter 2026 financial results. The company said it will issue an earnings press release earlier that morning.
Enovis Corporation is a medical technology company focused on developing clinically differentiated solutions for musculoskeletal health. Enovis Corporation designs, manufactures, and distributes medical devices and services used across the patient care continuum, including injury prevention, rehabilitation, pain management, physical therapy, and reconstructive surgery. Its product portfolio includes orthopedic braces and supports, recovery and rehabilitation technologies, joint replacement implants, and surgical enabling tools that support hip, knee, shoulder, elbow, foot, ankle, and other extremity procedures. The company serves healthcare professionals and patients through two main business segments, Prevention & Recovery and Reconstructive, reflecting its role in both non-surgical treatment and surgical care. Enovis Corporation operates in the orthopedic and broader medical device markets, where it provides solutions intended to improve mobility, restore function, and support clinical workflows across hospitals, outpatient settings, and other care environments.
CEO Mr. Damien McDonald · 7,802 employees · United States · https://www.enovis.com
